Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,974 | 17 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $620.02 | 6 | $0 (2021) |
| AbbVie, Inc. | $530.11 | 4 | $0 (2019) |
| QOL Medical, LLC | $299.99 | 2 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $131.00 | 1 | $0 (2023) |
| Gilead Sciences, Inc. | $124.98 | 1 | $0 (2018) |
| GlaxoSmithKline, LLC. | $123.95 | 1 | $0 (2018) |
| ALCRESTA THERAPEUTICS, INC. | $119.93 | 1 | $0 (2021) |
| SANOFI PASTEUR INC. | $24.44 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $131.00 | 1 | E.R. Squibb & Sons, L.L.C. ($131.00) |
| 2021 | $438.07 | 4 | QOL Medical, LLC ($299.99) |
| 2019 | $777.47 | 7 | AbbVie, Inc. ($395.31) |
| 2018 | $370.04 | 3 | Gilead Sciences, Inc. ($124.98) |
| 2017 | $257.84 | 2 | AbbVie, Inc. ($134.80) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/15/2023 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $131.00 | General |
| Category: Neuroscience | ||||||
| 10/21/2021 | ALCRESTA THERAPEUTICS, INC. | RELIZORB (Device) | Food and Beverage | In-kind items and services | $119.93 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/21/2021 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | In-kind items and services | $175.00 | General |
| Category: THERAPY FOR CSID | ||||||
| 06/29/2021 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: THERAPY FOR CSID | ||||||
| 02/23/2021 | Merck Sharp & Dohme Corporation | DIFICID (Drug), RECARBRIO, ZINPLAVA | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/05/2019 | Merck Sharp & Dohme Corporation | DIFICID (Drug), ZINPLAVA | Food and Beverage | In-kind items and services | $109.92 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/12/2019 | Merck Sharp & Dohme Corporation | DIFICID (Drug), ZINPLAVA | Food and Beverage | In-kind items and services | $124.76 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/30/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $133.13 | General |
| Category: Virology | ||||||
| 03/28/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $117.84 | General |
| Category: Virology | ||||||
| 03/14/2019 | Merck Sharp & Dohme Corporation | ZINPLAVA (Biological) | Food and Beverage | In-kind items and services | $123.04 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/26/2019 | SANOFI PASTEUR INC. | FLUBLOK QUADRIVALENT (Drug), FLUZONE HIGH-DOSE, ADACEL | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: VACCINES | ||||||
| 01/31/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $144.34 | General |
| Category: Virology | ||||||
| 08/07/2018 | Merck Sharp & Dohme Corporation | DIFICID (Drug), ZINPLAVA | Food and Beverage | In-kind items and services | $121.11 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/19/2018 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $124.98 | General |
| Category: HBV | ||||||
| 03/09/2018 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $123.95 | General |
| Category: VACCINES | ||||||
| 07/27/2017 | Merck Sharp & Dohme Corporation | DIFICID (Drug) | Food and Beverage | In-kind items and services | $123.04 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/16/2017 | AbbVie, Inc. | Viekira (Drug) | Food and Beverage | In-kind items and services | $134.80 | General |
| Category: Virology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 5 | 304 | 1,590 | $167,970 | $118,093 |
| 2020 | 5 | 308 | 1,521 | $154,140 | $111,499 |
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2021 | 120 | 912 | $77,560 | $58,087 | 74.9% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2021 | 68 | 550 | $68,630 | $45,932 | 66.9% |
| 99306 | Initial nursing facility visit, typically 45 minutes per day | Facility | 2021 | 77 | 77 | $17,650 | $11,723 | 66.4% |
| 99307 | Subsequent nursing facility visit, typically 10 minutes per day | Facility | 2021 | 28 | 40 | $3,005 | $1,614 | 53.7% |
| 99315 | Nursing facility discharge day management, 30 minutes or less | Facility | 2021 | 11 | 11 | $1,125 | $737.22 | 65.5% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2020 | 109 | 901 | $72,125 | $57,241 | 79.4% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2020 | 69 | 466 | $58,160 | $38,763 | 66.6% |
| 99306 | Initial nursing facility visit, typically 45 minutes per day | Facility | 2020 | 73 | 78 | $17,650 | $11,880 | 67.3% |
| 99307 | Subsequent nursing facility visit, typically 10 minutes per day | Facility | 2020 | 36 | 55 | $4,125 | $2,213 | 53.6% |
| 99315 | Nursing facility discharge day management, 30 minutes or less | Facility | 2020 | 21 | 21 | $2,080 | $1,402 | 67.4% |
About Dr. Linda Kamal, MD
Dr. Linda Kamal, MD is a Infectious Disease healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1598701963.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Linda Kamal, MD has received a total of $1,974 in payments from pharmaceutical and medical device companies, with $131.00 received in 2023. These payments were reported across 17 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($1,974).
As a Medicare-enrolled provider, Kamal has provided services to 612 Medicare beneficiaries, totaling 3,111 services with total Medicare billing of $229,592. Data is available for 2 years (2020–2021), covering 10 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location New York, NY
- Active Since 06/22/2006
- Last Updated 09/30/2011
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1598701963
Products in Payments
- DIFICID (Drug) $496.98
- Mavyret (Drug) $395.31
- SUCRAID (Drug) $299.99
- Viekira (Drug) $134.80
- ZEPOSIA (Drug) $131.00
- Vemlidy (Drug) $124.98
- SHINGRIX (Biological) $123.95
- ZINPLAVA (Biological) $123.04
- RELIZORB (Device) $119.93
- FLUBLOK QUADRIVALENT (Drug) $24.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in New York
Sian Jones, Md, MD
Infectious Disease — Payments: $349,236
Dr. David Bekhor, Md, MD
Infectious Disease — Payments: $309,279
Genovefa Papanicolaou, Md, MD
Infectious Disease — Payments: $183,179
Dr. Michelle Cespedes, M.d, M.D
Infectious Disease — Payments: $136,443
Mr. Jose Cortes, M.d, M.D
Infectious Disease — Payments: $123,792
Dr. Martin Markowitz, Md, MD
Infectious Disease — Payments: $112,821